LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akciju saraksts・Exelixis Inc

Exelixis Inc

Slēgts

SektorsVeselības aprūpe

50.42 -1.87

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

50.31

Max

51.02

Galvenie mērījumi
By Trading Economics
Ienākumi	-34M 210M
Pārdošana	12M 611M
P/E Sektora vidējais	16.606 50.102
EPS	0.87
Peļņas marža	34.457
Darbinieki	1,077
EBITDA	15M 258M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-5.51% downside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 27. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.4B 13B
Iepriekšējā atvēršanas cena	52.29
Iepriekšējā slēgšanas cena	50.42

Ziņu noskaņojums

By Acuity

50%

124 / 344 Rangs Healthcare

Exelixis Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. maijs 23:44 UTC

Tirgus saruna

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

2026. g. 31. maijs 23:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 31. maijs 23:36 UTC

Tirgus saruna

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

2026. g. 31. maijs 23:36 UTC

Tirgus saruna

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

2026. g. 31. maijs 22:54 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

2026. g. 29. maijs 23:08 UTC

Iegādes, apvienošanās, pārņemšana

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026. g. 29. maijs 23:06 UTC

Iegādes, apvienošanās, pārņemšana

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026. g. 29. maijs 20:53 UTC

Peļņas

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026. g. 29. maijs 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 20:33 UTC

Tirgus saruna

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026. g. 29. maijs 20:11 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 19:47 UTC

Peļņas

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026. g. 29. maijs 19:36 UTC

Tirgus saruna

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026. g. 29. maijs 19:22 UTC

Tirgus saruna

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026. g. 29. maijs 19:05 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026. g. 29. maijs 18:19 UTC

Tirgus saruna

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026. g. 29. maijs 18:12 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026. g. 29. maijs 18:11 UTC

Tirgus saruna

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026. g. 29. maijs 18:10 UTC

Tirgus saruna

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026. g. 29. maijs 17:55 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 17:55 UTC

Tirgus saruna

NEAR Protocol Nearly Doubles in May -- Market Talk

2026. g. 29. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026. g. 29. maijs 17:00 UTC

Peļņas

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 29. maijs 16:02 UTC

Tirgus saruna

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Exelixis Inc Prognoze

Cenas mērķis

By TipRanks

-5.51% uz leju

Prognoze 12 mēnešiem

Vidējais 47.7 USD -5.51%

Augstākais 56 USD

Zemākais 40 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Exelixis Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Exelixis Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

124 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.